Monte Rosa Therapeutics, Inc.
GLUE- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001826457
In the last 90 days, Monte Rosa Therapeutics, Inc. insiders filed 0 open-market purchases and 3 sales; 192 institutions reported holding it in 13F filings for Q2 2026, worth $2.24B in total; Duquesne Family Office is the only superinvestor holding it.
Q3 2021 vs. Q2 2021
How the institutions holding Monte Rosa Therapeutics, Inc. changed between Q2 2021 and Q3 2021.
All holders in Q3 2021All holders in Q2 2021
| Measure | Q2 2021 | Q3 2021 | Change |
|---|---|---|---|
| Holders | 48 | 56 | +8 |
| Shares | 32.1M | 34.9M | +2.80M (+8.7%) |
| Value | $705.1M | $759.4M | +$54.3M (+7.7%) |
New holders (28)
Institutions that held Monte Rosa Therapeutics, Inc. at the end of Q3 2021 but not at the end of Q2 2021.
Sold out (20)
Institutions that held Monte Rosa Therapeutics, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| Deerfield Management Company, L.P. (Series C) | 350,000 | $7.95M |
| OrbiMed Advisors LLC | 350,000 | $7.95M |
| Suvretta Capital Management, LLC | 150,000 | $3.40M |
| Sectoral Asset Management Inc | 129,633 | $2.94M |
| Ratan Capital Management LP | 120,000 | $2.72M |
| Monashee Investment Management LLC | 120,000 | $2.72M |
| HealthCor Management, L.P. | 100,000 | $2.27M |
| Pura Vida Investments, LLC | 100,000 | $2.27M |
| LMR Partners LLP | 58,500 | $1.33M |
| Hound Partners, LLC | 49,995 | $1.14M |
| Alyeska Investment Group, L.P. | 50,000 | $1.14M |
| Pinz Capital Management, LP | 43,700 | $992.0K |
| Norges Bank | 30,000 | $681.0K |
| Squarepoint Ops LLC | 28,209 | $640.0K |
| Point72 Asset Management, L.P. | 25,000 | $568.0K |
| Qube Research & Technologies Ltd | 13,100 | $297.0K |
| Point72 Hong Kong Ltd | 10,606 | $241.0K |
| Tudor Investment Corp Et Al | 10,000 | $227.0K |
| Maven Securities LTD | 11,106 | $213.0K |
| Wellington Management Group LLP | 9,192 | $209.0K |